Niktimvo marks the first FDA-approved therapy targeting CSF-1R to address inflammation and fibrosis in chronic ...

Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and ...

A new offering in collaboration with Progyny, Inc makes fertility/family-building services more accessible and equitable.

Pharmaceutical companies’ direct-to-patient (DTP) programs have recently sparked conversations and criticism in fear of their ...

Cary Claiborne, CEO, Adial Pharmaceuticals, discusses promising results of the AD04-13 study in patients with Alcohol Use Disorder ...

The New Drug Application for TAR-200 is supported by results from the Phase IIb SunRISe-1 study, which demonstrated an 83.5% ...

During the transition period, Lykos will work with a number of shareholders to secure financing for an additional Phase III ...

Waystar announced a new set of AI-powered tools designed to perform a variety of tasks, including appealing denied claims. 1 ...

New partnerships aim to expand Teva’s biosimilar portfolio and enhance access to high-cost biologics across key markets.

Moderna provided updates on key elements of its pipeline, including a next-generation COVID-19 vaccine, an RSV vaccine, a new ...

Acceptance of the Biologics License Application for subcutaneous Leqembi is based on results from the Clarity AD open-label ...

The Healthcare Businesswomen’s Association (HBA) announced that it has named Reshema Kemps-Polanco, executive vice president ...